SCHEMBL3487183

SCHEMBL3487183

COC(=O)c1cc(F)cc(OCC(=O)O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.48
HPGD P15428 1/20 0.44
PTPRB P23467 1/20 0.44
HSD17B10 Q99714 1/20 0.44
LMNA P02545 3/20 0.44
MRGPRX4 Q96LA9 1/20 0.44
MAPT P10636 4/20 0.43
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ATM Q13315 1/20 0.43
PKM P14618 1/20 0.42
HTT P42858 1/20 0.42
POLB P06746 1/20 0.42
BLM P54132 1/20 0.42
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8271753 0.89 ATM (0.51) HPGDPTPRBHSD17B10LMNAMAPT
SCHEMBL4585878 0.83 CA12 (0.59) HPGDPTPRBHSD17B10LMNAMAPT
SCHEMBL6977750 0.81 NOTUM (0.49) HPGDPTPRBHSD17B10LMNAMAPT
SCHEMBL4739457 0.81 LDHA (0.55) LDHAHPGDPTPRBHSD17B10LMNA
SCHEMBL31521762 0.80 CA1 (0.52) HPGDLMNAMRGPRX4MAPTRAB9A
SCHEMBL17462467 0.80 CA1 (0.52) HPGDLMNAMRGPRX4MAPTRAB9A
SCHEMBL16141851 0.79 KAT6A (0.52) LMNAMRGPRX4MAPTRAB9ANPC1
SCHEMBL712175 0.77 GCK (0.53) HPGDLMNAMAPTRAB9ANPC1
SCHEMBL521670 0.77 CA1 (0.58) LMNAMAPTRAB9ANPC1ATM
SCHEMBL1401499 0.77 CA1 (0.58) HSD17B10LMNAMAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2138484-B1 FUSED BICYCLIC HETEROARYL DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2015-08-26 EP disclosed
US-20130035337-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-02-07 US disclosed
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-02-25 US disclosed
EP-2138484-A1 FUSED BICYCLIC HETEROARYL DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035337-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE PPARG, GPR119, PPARA LDHA 1289/4885HPGD 1464/4885PTPRB 2146/4885
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE PPARG, GPR119, PPARA LDHA 1289/4885HPGD 1464/4885PTPRB 2146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.